KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Capital Expenditures (2016 - 2025)

Novavax (NVAX) has 16 years of Capital Expenditures data on record, last reported at -$3.5 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 540.44% year-over-year to -$3.5 million; the TTM value through Sep 2025 reached $2.9 million, down 58.66%, while the annual FY2024 figure was $1.1 million, 86.54% down from the prior year.
  • Capital Expenditures reached -$3.5 million in Q4 2025 per NVAX's latest filing, down from $3.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $48.1 million in Q3 2022 and bottomed at -$62.1 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $882000.0, with a median of $226500.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: surged 10924.8% in 2021, then tumbled 1167.69% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at -$4.9 million in 2021, then crashed by 1167.69% to -$62.1 million in 2022, then soared by 108.86% to $5.5 million in 2023, then plummeted by 109.88% to -$544000.0 in 2024, then plummeted by 540.44% to -$3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$3.5 million in Q4 2025, $3.4 million in Q3 2025, and $81000.0 in Q2 2025.